Royalty Pharma Plc Stock Price To Earnings To Growth

RPRX Stock

USD 26.43 0.03 0.11%

Royalty Pharma Plc fundamentals help investors to digest information that contributes to Royalty Pharma's financial success or failures. It also enables traders to predict the movement of Royalty Stock. The fundamental analysis module provides a way to measure Royalty Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Royalty Pharma stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Royalty Pharma Plc Company Price To Earnings To Growth Analysis

Royalty Pharma's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Current Royalty Pharma Price To Earnings To Growth

5.51 X

Most of Royalty Pharma's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Royalty Pharma Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Royalty Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Royalty Pharma is extremely important. It helps to project a fair market value of Royalty Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Royalty Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Royalty Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Royalty Pharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Net Debt	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue	Capital Surpluse
Total Assets		0.98	0.8	0.32	0.95	-0.24	0.21	-0.36	-0.17	0.93	0.92	0.88	0.7	0.13	0.35	0.29	0.63	0.85	0.82	-0.83	-0.23	0.44	-0.39	0.6
Total Stockholder Equity	0.98		0.83	0.29	0.91	-0.25	0.26	-0.35	-0.13	0.91	0.91	0.82	0.67	0.01	0.27	0.17	0.53	0.8	0.76	-0.77	-0.27	0.32	-0.38	0.51
Accounts Payable	0.8	0.83		-0.18	0.71	-0.23	0.06	-0.25	-0.32	0.74	0.79	0.45	0.83	0.05	0.6	0.37	0.71	0.83	0.79	-0.74	-0.6	0.19	-0.74	0.71
Short Term Investments	0.32	0.29	-0.18		0.27	0.35	-0.01	-0.39	0.09	0.27	0.27	0.49	0.0	0.13	-0.5	-0.14	-0.02	0.2	0.14	-0.26	0.49	0.52	0.53	-0.15
Total Liab	0.95	0.91	0.71	0.27		-0.34	0.46	-0.37	-0.03	0.96	0.92	0.91	0.67	0.16	0.32	0.28	0.63	0.73	0.65	-0.66	-0.29	0.41	-0.32	0.54
Treasury Stock	-0.24	-0.25	-0.23	0.35	-0.34		-0.42	-0.68	0.09	-0.32	-0.3	-0.26	-0.2	0.0	-0.06	-0.04	-0.16	-0.09	-0.03	0.01	0.24	0.0	0.1	-0.07
Common Stock	0.21	0.26	0.06	-0.01	0.46	-0.42		-0.18	0.53	0.42	0.37	0.37	0.07	-0.22	-0.27	-0.27	-0.07	-0.21	-0.35	0.35	-0.31	-0.2	0.18	-0.28
Property Plant Equipment	-0.36	-0.35	-0.25	-0.39	-0.37	-0.68	-0.18		-0.3	-0.36	-0.35	-0.33	-0.26	-0.04	-0.12	-0.1	-0.23	-0.28	-0.25	0.25	0.12	-0.14	0.13	-0.2
Intangible Assets	-0.17	-0.13	-0.32	0.09	-0.03	0.09	0.53	-0.3		-0.07	-0.12	0.03	-0.34	-0.27	-0.36	-0.39	-0.4	-0.46	-0.49	0.47	0.05	-0.33	0.34	-0.47
Net Tangible Assets	0.93	0.91	0.74	0.27	0.96	-0.32	0.42	-0.36	-0.07		0.98	0.83	0.74	0.05	0.3	0.28	0.65	0.78	0.65	-0.67	-0.39	0.41	-0.26	0.6
Retained Earnings	0.92	0.91	0.79	0.27	0.92	-0.3	0.37	-0.35	-0.12	0.98		0.75	0.81	0.04	0.27	0.27	0.69	0.82	0.67	-0.68	-0.46	0.41	-0.29	0.59
Total Current Assets	0.88	0.82	0.45	0.49	0.91	-0.26	0.37	-0.33	0.03	0.83	0.75		0.37	0.19	0.15	0.18	0.38	0.58	0.58	-0.63	0.1	0.45	-0.1	0.37
Net Debt	0.7	0.67	0.83	0.0	0.67	-0.2	0.07	-0.26	-0.34	0.74	0.81	0.37		0.3	0.49	0.49	0.93	0.84	0.69	-0.66	-0.65	0.48	-0.58	0.72
Long Term Debt	0.13	0.01	0.05	0.13	0.16	0.0	-0.22	-0.04	-0.27	0.05	0.04	0.19	0.3		0.18	0.78	0.52	0.27	0.33	-0.3	0.3	0.82	-0.41	0.36
Net Receivables	0.35	0.27	0.6	-0.5	0.32	-0.06	-0.27	-0.12	-0.36	0.3	0.27	0.15	0.49	0.18		0.49	0.65	0.57	0.64	-0.57	-0.48	0.03	-0.76	0.82
Long Term Debt Total	0.29	0.17	0.37	-0.14	0.28	-0.04	-0.27	-0.1	-0.39	0.28	0.27	0.18	0.49	0.78	0.49		0.66	0.53	0.56	-0.5	0.02	0.72	-0.61	0.75
Net Invested Capital	0.63	0.53	0.71	-0.02	0.63	-0.16	-0.07	-0.23	-0.4	0.65	0.69	0.38	0.93	0.52	0.65	0.66		0.83	0.73	-0.7	-0.51	0.61	-0.63	0.84
Long Term Investments	0.85	0.8	0.83	0.2	0.73	-0.09	-0.21	-0.28	-0.46	0.78	0.82	0.58	0.84	0.27	0.57	0.53	0.83		0.95	-0.95	-0.32	0.57	-0.54	0.85
Short Long Term Debt	0.82	0.76	0.79	0.14	0.65	-0.03	-0.35	-0.25	-0.49	0.65	0.67	0.58	0.69	0.33	0.64	0.56	0.73	0.95		-0.99	-0.14	0.53	-0.63	0.85
Capital Stock	-0.83	-0.77	-0.74	-0.26	-0.66	0.01	0.35	0.25	0.47	-0.67	-0.68	-0.63	-0.66	-0.3	-0.57	-0.5	-0.7	-0.95	-0.99		0.08	-0.56	0.52	-0.81
Net Working Capital	-0.23	-0.27	-0.6	0.49	-0.29	0.24	-0.31	0.12	0.05	-0.39	-0.46	0.1	-0.65	0.3	-0.48	0.02	-0.51	-0.32	-0.14	0.08		0.3	0.4	-0.36
Short Term Debt	0.44	0.32	0.19	0.52	0.41	0.0	-0.2	-0.14	-0.33	0.41	0.41	0.45	0.48	0.82	0.03	0.72	0.61	0.57	0.53	-0.56	0.3		-0.16	0.47
Current Deferred Revenue	-0.39	-0.38	-0.74	0.53	-0.32	0.1	0.18	0.13	0.34	-0.26	-0.29	-0.1	-0.58	-0.41	-0.76	-0.61	-0.63	-0.54	-0.63	0.52	0.4	-0.16		-0.66
Capital Surpluse	0.6	0.51	0.71	-0.15	0.54	-0.07	-0.28	-0.2	-0.47	0.6	0.59	0.37	0.72	0.36	0.82	0.75	0.84	0.85	0.85	-0.81	-0.36	0.47	-0.66

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Royalty Pharma

Royalty Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

0.003435

At this time, Royalty Pharma's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Royalty Pharma Plc has a Price To Earnings To Growth of 5.5139 times. This is much higher than that of the Pharmaceuticals sector and 75.6% higher than that of the Health Care industry. The price to earnings to growth for all United States stocks is 12.76% lower than that of the firm.

Royalty Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Royalty Pharma's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Royalty Pharma could also be used in its relative valuation, which is a method of valuing Royalty Pharma by comparing valuation metrics of similar companies.

Royalty Pharma is currently under evaluation in price to earnings to growth category among its peers.

Royalty Pharma ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Royalty Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Royalty Pharma's managers, analysts, and investors.

Environmental

Governance

Social

Royalty Fundamentals

	Return On Equity	0.17
	Return On Asset	0.0569
	Profit Margin	0.51 %
	Operating Margin	1.30 %
	Current Valuation	17.59 B
	Shares Outstanding	444.3 M
	Shares Owned By Insiders	13.16 %
	Shares Owned By Institutions	72.76 %
	Number Of Shares Shorted	14.55 M
	Price To Earning	37.70 X
	Price To Book	1.71 X
	Price To Sales	6.87 X
	Revenue	2.35 B
	Gross Profit	1.33 B
	EBITDA	1.89 B
	Net Income	1.13 B
	Cash And Equivalents	1.47 B
	Cash Per Share	3.34 X
	Total Debt	6.14 B
	Debt To Equity	0.68 %
	Current Ratio	2.07 X
	Book Value Per Share	15.40 X
	Cash Flow From Operations	2.99 B
	Short Ratio	8.05 X
	Earnings Per Share	2.54 X
	Price To Earnings To Growth	5.51 X
	Target Price	41.53
	Beta	0.47
	Market Capitalization	15.57 B
	Total Asset	16.38 B
	Retained Earnings	2.52 B
	Working Capital	1.11 B
	Current Asset	10.66 M
	Current Liabilities	2.31 M
	Annual Yield	0.03 %
	Net Asset	16.38 B
	Last Dividend Paid	0.83

About Royalty Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Royalty Pharma Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Royalty Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Royalty Pharma Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC